JP2013542261A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542261A5
JP2013542261A5 JP2013538872A JP2013538872A JP2013542261A5 JP 2013542261 A5 JP2013542261 A5 JP 2013542261A5 JP 2013538872 A JP2013538872 A JP 2013538872A JP 2013538872 A JP2013538872 A JP 2013538872A JP 2013542261 A5 JP2013542261 A5 JP 2013542261A5
Authority
JP
Japan
Prior art keywords
hydrogen
pharmaceutically acceptable
acceptable salt
compound according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013538872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/060083 external-priority patent/WO2012064911A1/en
Publication of JP2013542261A publication Critical patent/JP2013542261A/ja
Publication of JP2013542261A5 publication Critical patent/JP2013542261A5/ja
Ceased legal-status Critical Current

Links

JP2013538872A 2010-11-12 2011-11-10 ピペリジノンカルボキサミドインダンcgrp受容体アンタゴニスト Ceased JP2013542261A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41308210P 2010-11-12 2010-11-12
US61/413,082 2010-11-12
US201061425039P 2010-12-20 2010-12-20
US61/425,039 2010-12-20
PCT/US2011/060083 WO2012064911A1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide indane cgrp receptor antagonists

Publications (2)

Publication Number Publication Date
JP2013542261A JP2013542261A (ja) 2013-11-21
JP2013542261A5 true JP2013542261A5 (enExample) 2014-12-25

Family

ID=46051295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538872A Ceased JP2013542261A (ja) 2010-11-12 2011-11-10 ピペリジノンカルボキサミドインダンcgrp受容体アンタゴニスト

Country Status (6)

Country Link
US (2) US8883807B2 (enExample)
EP (1) EP2637656B1 (enExample)
JP (1) JP2013542261A (enExample)
AU (1) AU2011326455A1 (enExample)
CA (1) CA2816974A1 (enExample)
WO (1) WO2012064911A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011326455A1 (en) * 2010-11-12 2013-05-23 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane CGRP receptor antagonists
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2686324B1 (en) * 2011-03-18 2016-01-06 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20250028525A (ko) * 2012-03-14 2025-02-28 머크 샤프 앤드 돔 엘엘씨 Cgrp 수용체 길항제의 제조 방법
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
CA2937315A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2019093284A1 (ja) * 2017-11-07 2019-05-16 キッセイ薬品工業株式会社 縮合複素環化合物
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
TWI847671B (zh) * 2022-04-29 2024-07-01 大陸商熙源安健醫藥(北京)有限公司 哌啶甲醯胺氮雜茚滿類衍生物及其製備方法和用途
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine
CN119431222B (zh) * 2024-11-04 2025-10-17 杭州澳赛诺生物科技有限公司 一种不对称合成乌布吉泮手性中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082602A2 (en) * 2003-03-14 2004-09-30 Merck & Co. Inc. Carboxamide spirohydantoin cgrp receptor antagonists
AU2005282466B2 (en) * 2004-09-08 2011-03-10 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
AU2006223236A1 (en) 2005-03-14 2006-09-21 Merck Sharp & Dohme Corp. CGRP receptor antagonists
CA2673108A1 (en) * 2006-12-08 2008-06-19 Merck & Co., Inc. Constrained spirocyclic compounds as cgrp receptor antagonists
WO2008153849A1 (en) * 2007-06-05 2008-12-18 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
AU2011326455A1 (en) * 2010-11-12 2013-05-23 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane CGRP receptor antagonists

Similar Documents

Publication Publication Date Title
JP2013542261A5 (enExample)
JP2014511892A5 (enExample)
JP2013510120A5 (enExample)
JP2014114295A5 (enExample)
JP2016525102A5 (enExample)
JP2012144574A5 (enExample)
JP2013537203A5 (enExample)
JP2016516043A5 (enExample)
JP2016503793A5 (enExample)
JP2013518107A5 (enExample)
JP2014511891A5 (enExample)
JP2013509429A5 (enExample)
JP2014508811A5 (enExample)
JP2014500861A5 (enExample)
JP2011500758A5 (enExample)
JP2016513696A5 (enExample)
JP2012513416A5 (enExample)
JP2015509075A5 (enExample)
JP2018537535A5 (enExample)
JP2016540749A5 (enExample)
JP2011088926A5 (enExample)
JP2019516739A5 (enExample)
JP2014516033A5 (enExample)
JP2019505529A5 (enExample)
JP2016537338A5 (enExample)